Viveve Medical, Inc. (“Viveve”), a medical technology company focused on women’s health, today announced six new distribution partnerships that expand commercial availability of the Viveve System to fourteen additional countries in Latin America. The new relationships provide for distribution of the Viveve System in: Argentina, Peru, Paraguay (Sirex S.A.) and Chile (Torregal), Columbia and Ecuador (Alphaeon Columbia S.A.S.), Mexico (Vitre-Tech), Panama, Costa Rica, Guatemala and Dominican Republic (Coolmed, S.A.), Uruguay (Adenor, S.A.), and Venezuela and the Caribbean (MARC Group International, LLC).
“The Latin American region represents one of the world’s largest markets for aesthetic medical procedures,” said Jim Atkinson, president and chief business officer of Viveve. “Our collaboration with a distinguished group of distribution partners will help us to increase our presence in the region while providing outstanding service and customer support.”

While Kegel exercises are frequently prescribed for the treatment of vaginal laxity, they actually target the muscles of the pelvic floor that have been weakened during childbirth, potentially causing urinary control problems. These muscles also support or “hold-up” the pelvic organs and prevent them from sagging. Therefore, Kegel exercises do not address vaginal laxity; they address pelvic floor muscle, not the tissue within the vagina or the vaginal opening (introital tissue).

The surgical options currently available to women include significant recovery time and post-procedure pain. As with any invasive procedure, these options may also involve a variety of serious health risks and can include high out-of-pocket financial costs.

The Viveve Treatment for vaginal laxity offers an alternative to surgery. It is an office-based non-surgical, painless medical procedure for treating vaginal laxity. A physician performs the treatment using the Viveve System that works by cooling and gently heating vaginal tissue. In clinical trials involving a total of 54 women undertaken in 2010 and 2012, the Viveve Treatment improved vaginal laxity in 88% of women.
Viveve now has 23 exclusive partnerships covering distribution in 65 countries around the world and has received regulatory clearance for the Viveve System in 25 of those countries thus far.
“We believe the combination of our internationally patented technology, the experience and professionalism of our partners, and the acceptance of innovative medical procedures in all of our target markets will advance Viveve’s reputation as a leading provider of women’s health products in this important region,” said Patricia Scheller, chief executive officer of Viveve. “Available safety and efficacy data continue to support the use of Viveve Treatment as a painless procedure to treat the common condition of vaginal laxity, which can profoundly impact a woman’s sexual satisfaction and quality of life.”

About Viveve

Viveve Medical, Inc., is a women’s health company passionately committed to advancing new solutions to improve women’s overall well-being and quality of life. The company’s lead product, the internationally patented Viveve System, is a non-surgical, non-ablative medical device that remodels collagen and restores tissue with only one treatment session.

The Viveve System treats the condition of vaginal laxity that can result in decreased physical sensation and sexual satisfaction. Physician surveys indicate that vaginal laxity is the number one post-delivery physical change for women, being more prevalent than weight gain, urinary incontinence or stretch marks.

The Viveve Treatment uses patented, reverse-thermal gradient radiofrequency technology to restore vaginal tissue in one 30-minute out-patient treatment in a physician’s office. The Viveve System has received regulatory approval in many countries throughout the world and is available through physician import license in Japan. It is currently not available for sale in the U.S. For more information, please visit Viveve’s website at www.viveve.com.

SUNNYVALE, CA–(Marketwired – July 05, 2016) –